文献速递白血病

DOT1L抑制剂pinometostat降低H3K79甲基化并在成人急性白血病中具有适度临床活性

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
PubMed 文献 · Blood · 2018-05-03

本研究为1期临床试验,评估pinometostat(EPZ-5676)在成人晚期急性白血病(尤其MLL基因重排)患者中的安全性和疗效。51例患者入组6个剂量递增队列(n=26)和2个扩展队列(n=25),剂量为54和90 mg/m²/天持续静脉输注。最常见不良事件为疲乏(39%)、恶心(39%)、便秘(35%)和发热性中性粒细胞减少(35%)。2例t(11;19)患者在54 mg/m²/天剂量下达到完全缓解,单药疗效适度,未达到最大耐受剂量。

要点

  • pinometostat在MLL-r急性白血病中显示出概念验证性疗效,2例t(11;19)患者达到完全缓解。
  • 单药疗效适度,未达到最大耐受剂量,最常见不良事件为疲乏、恶心、便秘和发热性中性粒细胞减少。
  • 该研究为DOT1L靶向治疗MLL-r白血病奠定基础,支持未来联合治疗策略。

核心结论

  • pinometostat单药给药总体安全,未达到最大耐受剂量,但单药疗效适度。
  • 2例t(11;19)患者在54 mg/m²/天持续静脉输注下达到完全缓解,证明靶向DOT1L在MLL-r白血病中可产生有临床意义的缓解。
  • 本研究展示了靶向DOT1L治疗MLL-r白血病的治疗潜力,并为未来联合治疗策略奠定基础。

研究设计与样本

  • 1期临床试验,评估pinometostat在成人晚期急性白血病患者中的安全性和疗效。
  • 51例患者入组6个剂量递增队列(n=26)和2个扩展队列(n=25)。
  • pinometostat剂量为54和90 mg/m²/天,持续静脉输注,28天为一周期。
  • 因剂量递增阶段未确定最大耐受剂量,扩展队列剂量基于安全性、临床反应数据及剂量递增期间H3K79甲基化降低的药效学证据选择。
  • 临床试验注册号NCT01684150。

主要发现

  • 在所有剂量水平,pinometostat血浆浓度呈近似剂量比例增加,输注后4-8小时达到表观稳态,治疗停止后迅速下降。
  • 任何原因的最常见不良事件为疲乏(39%)、恶心(39%)、便秘(35%)和发热性中性粒细胞减少(35%)。
  • 2例t(11;19)患者在54 mg/m²/天持续静脉输注下达到完全缓解。
  • 未达到最大耐受剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 单药疗效适度。
  • 未达到最大耐受剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (MLL) gene rearrangements (MLL-r) resulting from 11q23 translocations. Fifty-one patients were enrolled into 6 dose-escalation cohorts (n = 26) and 2 expansion cohorts (n = 25) at pinometostat doses of 54 and 90 mg/m2 per day by continuous intravenous infusion in 28-day cycles. Because a maximum tolerated dose was not established in the dose-escalation phase, the expansion doses were selected based on safety and clinical response data combined with pharmacodynamic evidence of reduction in H3K79 methylation during dose escalation. Across all dose levels, plasma pinometostat concentrations increased in an approximately dose-proportional fashion, reaching an apparent steady-state by 4-8 hours after infusion, and rapidly decreased following treatment cessation. The most common adverse events, of any cause, were fatigue (39%), nausea (39%), constipation (35%), and febrile neutropenia (35%). Overall, 2 patients, both with t(11;19), experienced complete remission at 54 mg/m2 per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in MLL-r leukemia patients. Administration of pinometostat was generally safe, with the maximum tolerated dose not being reached, although efficacy as a single agent was modest. This study demonstrates the therapeutic potential for targeting DOT1L in MLL-r leukemia and lays the groundwork for future combination approaches in this patient population. This clinical trial is registered at www.clinicaltrials.gov as NCT01684150.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018. PMID: 29724899. doi:10.1182/blood-2017-12-818948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。